10x Genomics (TXG) Accumulated Expenses (2018 - 2026)

10x Genomics (TXG) has 9 years of Accumulated Expenses data on file, last reported at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 25.95% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (down 25.95% YoY), and the FY2025 full-year result was $40.0 million, down 2.9% from the prior year.
• Accumulated Expenses fell to $33.7 million in Q1 2026, from $40.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $59.8 million in Q4 2022 to a low of $20.7 million in Q1 2024.
• A 5-year average of $37.6 million and a median of $37.8 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 162.16% in 2022 and slumped 56.38% in 2024, its largest moves.
• Tracing TXG's Accumulated Expenses over 5 years: stood at $59.8 million in 2022, then plunged by 49.64% to $30.1 million in 2023, then jumped by 36.74% to $41.2 million in 2024, then declined by 2.9% to $40.0 million in 2025, then fell by 15.74% to $33.7 million in 2026.
• Business Quant data shows TXG's Accumulated Expenses at $33.7 million in Q1 2026, $40.0 million in Q4 2025, and $35.8 million in Q3 2025.